Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/20/2018 04/23/2018 04/24/2018 04/25/2018 04/26/2018 Date
1430(c) 1445(c) 1462.2(c) 1412.2(c) 1423.8 Last
9 782 267 7 883 176 10 450 607 18 400 623 3 955 199 Volume
+1.61% +1.05% +1.19% -3.42% +0.82% Change
More quotes
Financials (GBP)
Sales 2018 30 586 M
EBIT 2018 8 143 M
Net income 2018 3 877 M
Debt 2018 18 072 M
Yield 2018 5,67%
Sales 2019 31 412 M
EBIT 2019 8 481 M
Net income 2019 4 429 M
Debt 2019 16 960 M
Yield 2019 5,69%
P/E ratio 2018 17,40
P/E ratio 2019 15,04
EV / Sales2018 2,96x
EV / Sales2019 2,85x
Capitalization 72 510 M
More Financials
Company
GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
04/25 | 01:00pmEarnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
04/25Shire willing to back $64 billion Takeda bid, market signals doubts
RE
04/25GLAXOSMITHKLINE : 1Q Earnings Impacted by FX Effects -- Earnings Review
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/25LIBERTY PROPERTY TRUST : GSK building in South Philly's Navy Yard to be latest s..
AQ
04/25Shire willing to back $64 billion Takeda bid, market signals doubts
RE
04/25GLAXOSMITHKLINE : 1Q Profit and Revenue Falls, Backs Guidance
DJ
04/25GSK rules out entering Shire takeover battle
RE
04/25GLAXOSMITHKLINE : Pediatric Vaccine Stockpile Program
AQ
04/25GLAXOSMITHKLINE : GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
PU
04/25Shire bid marks Takeda's latest - and biggest - push for global status
RE
More news
Sector news : Pharmaceuticals - NEC
08:35aBP Appoints New Chairman to Start January 2019
DJ
08:25aBP names Lund to succeed Svanberg as chairman
RE
08:17aROCHE : lifts sales forecast as new drugs offset generics
RE
08:17aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08:05aCorrection to Roche Article on 1Q Sales
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE 
GLAXOSMITHKLINE  - 2015
This could be the time to buy
BUY
GLAXOSMITHKLINE - 2014
Bearish signal below GBp 1415
SELL
More Strategies
Latest Tweets
04/25GSK boss rethinking R&D incentives, as Barron and Sin seek out early ..
1
04/25Theravance Biopharma $TBPH Highlights Approval of Expanded Indication in the .. 
04/25Extraordinary scenes in . Sir Tom Scholar and Philip Hampton struggle to defe..
15
04/25Wednesday's newsmakers: Boeing crushes estimates and Comcast makes a formal o..
1
04/25Currency and pricing squeeze GlaxoSmithKline as new shingles vaccine shines
4
More tweets
Qtime:229
News from SeekingAlpha
04/25GlaxoSmithKline Plc (GSK) Q1 2018 Results - Earnings Call Transcript 
04/25A New Generation Of Novel HIV Small-Molecule Antivirals 
04/25FDA accepts Sanofi Pasteur's marketing application for expanded use of flu va.. 
04/25GlaxoSmithKline 2018 Q1 - Results - Earnings Call Slides 
04/25GlaxoSmithKline Q1 revenues and non-GAAP EPS down 2%; shares down 2% premarke.. 
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 15,5  GBP
Spread / Average Target 9,5%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE10.56%101 094
JOHNSON & JOHNSON-9.28%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398